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Available online 24 May 2016Ovarian cancer is commonly diagnosed at an advanced stage, with disease involving the upper abdomen. The
ﬁnding of enlarged cardiophrenic lymph nodes (CPLNs) on pre-operative imaging often indicates the presence
of malignant spread to the mediastinum. Surgical resection of CPLN through a transdiaphragmatic approach
can help to achieve cytoreduction to no gross residual. A retrospective chart reviewwas conducted on all patients
who underwent transdiaphragmatic cardiophrenic lymph node resection from 8/1/11 through 2/1/15. All rele-
vant pre-, intra-, and post-operative characteristics and ﬁndingswere recorded. A brief description of the surgical
technique is included for reference. Eleven patients were identiﬁed who had undergone transdiaphragmatic re-
section of cardiophrenic lymph nodes. Malignancywas identiﬁed in 18/21 (86%) of total lymph nodes submitted.
Themedian number of post-operative dayswas 7. The overall post-operativemorbidity associatedwith CPLN re-
section was low, with the most common ﬁnding being a small pleural effusion present on chest x-ray between
POD# 3–5 (55%). Transdiaphragmatic CPLN resection is a feasible procedure with relatively minor short-term
post-operative morbidities that can be used to achieve cytoreduction to no gross residual disease.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Cancer of the ovary is a particularly insidious disease that is com-
monly diagnosed at an advanced stage. In 2015, the American Cancer
Society estimated that 21,290 new cases were diagnosed and 14,180
women died of this disease (American Cancer Society, Inc. Cancer
Facts, and Figures, 2015). One of the main reasons for such a high asso-
ciated mortality is that approximately 65% of patients are initially diag-
nosed at International Federation of Gynecology and Obstetrics (FIGO)
Stage III or IV (Pecorelli et al., 1998). Primary cytoreductive surgery to
no gross residual (NGR) disease has consistently been found to be one
of the most important prognostic indicators in patients with advanced
stage ovarian cancer and remains the only factor under the control of
the operating surgeon. Furthermore, statistically signiﬁcant differences
in recurrence and survival have been observed when residual tumor
volume was reported as either microscopic (NGR), 0.1 to 5.0 cm, or
N5.0 cm (Winter et al., 2008).
Various surgical techniques have previously been described to
achieve complete resection of diaphragmatic and CPLN related disease.
Bashir et al. described a procedure for full thickness diaphragm resec-
tion which in addition to removing bulky diaphragm disease, allowedvine, 101 The City Drive Blvd.,
. This is an open access article underfor access to the pleural and pericardial space (Bashir et al., 2010). In ad-
dition, our group recently published a surgical video displaying the
technique of diaphragm resection and transdiaphragmatic resection of
CPLNs (LaFargue and Bristow, 2015). Video-assisted thoracic surgery
(VATS) has also been shown to be a successful modality for achieving
resection of CPLNs (Lim et al., 2009).
The current case series was compiled to further deﬁne the pre-,
intra-, and post-operative characteristics of patients undergoing
transdiaphragmatic resection of CPLNs in advanced gynecologic cancer
and delineate the associated short-term morbidities and time to adju-
vant chemotherapy.
2. Methods
The study design was a retrospective review performed in the divi-
sion of Gynecologic Oncology at the University of California IrvineMed-
ical Center. All patients who underwent a transdiaphragmatic
cardiophrenic lymph node resection from 8/1/11 through 2/1/15 as
part of a primary or secondary cytoreductive surgery were selected for
detailed review. Each identiﬁed subject had transdiaphragmatic CPLN
resection performed in an effort to achieve cytoreduction to no gross re-
sidual disease. There were only two different physicians who were
listed as the primary surgeon for all patients included in this report.
All of the CPLN resection procedureswere performed by the same gyne-
cologic oncologist with the assistance of either the primary surgeon or athe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 2. Cardiophrenic fat pad is grasped with Babcock clamp and excised using vessel
sealing-cutting device via diaphragmatic defect.
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placement prior to closing the diaphragmatic defect was determined
by the operating surgeon according to intra-operative ﬁndings and the
overall patient status.
Individual subject data encompassing pre-, intra-, and post-opera-
tive characteristics were identiﬁed through electronic medical record
review of inpatient and ambulatory records. Pre-operative data
reviewed included: patient's age, initial CA-125, presence and size of
CPLN on initial imaging, primary vs. recurrent cancer status, presumed
stage, histology (if known), and whether neoadjuvant chemotherapy
was given. Intra-operative characteristics were identiﬁed from opera-
tive notes and included: total operative time, estimated blood loss,
amount of residual disease at conclusion, placement of prophylactic
chest tube, and all ancillary procedures performed, including whether
hyperthermic intraperitoneal chemotherapy (HIPEC) was performed
at the conclusion of the operation. When an intra-operative frozen sec-
tion was sent on the CPLN specimen, the initial diagnosis was recorded
and included for analysis of congruence with ﬁnal pathology. Pathology
records were interrogated to determine the size and number of CPLNs
obtained from each patient. Post-operative characteristics were identi-
ﬁed through radiology and pathology reports as well as discharge sum-
maries and included:ﬁnal FIGO stage and histology, presence and size of
pleural effusions or pneumothorax, all major complications, post-oper-
ative day of discharge, and time to adjuvant chemotherapy.
2.1. Surgical technique
In most cases, enlarged cardiophrenic lymph nodes were ﬁrst iden-
tiﬁed on pre-operative CT imaging (Fig. 1). For the patients in which
pre-operative imaging did not show lymphadenopathy, the decision
was made to proceed with CPLN resection based on an intraoperative
assessment consisting of the degree of diaphragm involvement and pal-
pation of the pericardial space. The surgical technique used to perform
full-thickness diaphragm resection and CPLN resection has been previ-
ously described and illustrated (Bashir et al., 2010; LaFargue and
Bristow, 2015). In brief, full exposure of the diaphragm peritoneum is
achieved after mobilization the liver. The diaphragm is then incised
using electrocautery, the pleural space is explored, and the
cardiophrenic nodes are resected using a vessel sealing-cutting device
(Fig. 2). A 15F, round Jackson Pratt (JP) drain is then used as an alterna-
tive to the standard chest tube and placed through the diaphragmatic
defect into the pleural cavity under direct vision and brought out
through a separate stab incision in the mid-axillary line above the sev-
enth or eighth rib. The diaphragmatic defect is then closed using a
non-absorbable suture (2–0 polypropylene in ﬁgure-of-eight stitches).
The Jackson-Pratt drain is then connected to suction to evacuate the
pneumothorax. If no chest tube is placed, prior to tying the last stitch,Fig. 1. Pre-operative CT scan demonstrating enlarged cardiophrenic lymph node in
mediastinum.a fenestrated 16F Robinson catheter attached to wall suction is placed
into the pleural cavity to remove the pneumothorax and withdrawn
as the last knot is tied. The “bubble test” is then performed to evaluate
for any air leak by ﬁlling the right upper quadrant with saline solution
and delivering several large mechanical inspiratory breaths while
inspecting the repair for extravasation of air bubbles. If present, air
leaks are oversewn, the pneumothorax evacuated, and the test
repeated.
3. Results
3.1. Patient demographics
A total of 11 patients underwent transdiaphragmatic CPLN resection
(10 with unilateral CPLN resection, and 1 patient with bilateral resec-
tion). Speciﬁc patient characteristics are displayed in Table 1. The
mean agewas 58 years (range 42–71 years), with FIGO stage IVB serous
ovarian cancer being the most common stage, histology, and primary
tumor site, respectively. One patient included in the study had clear
cell uterine cancer. Enlarged cardiophrenic lymphnodeswere identiﬁed
in 7 patients on pre-operative imaging (64%), while the remainder was
identiﬁed based on intra-operative suspicion.
3.2. Surgical outcomes
Table 2 displays the intra-operative and post-operative ﬁndings. The
average operative time was 385 min (range 277–568 min), and the av-
erage estimated blood loss was 564 cm3 (range 200–900 cm3). Ten pa-
tients underwent optimal cytoreduction deﬁned as b1 cm (91%), while
7 of these patients had no gross residual disease (64%). A prophylactic
Jackson-Pratt drain was placed in the pleural cavity, as an alternative
chest tube, and brought out through a separate stab incision in the
chest in 8 patients (73%).
Intra-operative frozen section of the resected CPLNs was sent in 6
patients, with malignancy being identiﬁed in 5 of them. On ﬁnal patho-
logic evaluation, the average number and size of CPLNs obtained per pa-
tient was 1.9 (range 1–4) and 1.6 cm (range 0.2–2.5 cm), respectively,
with ﬁnal diagnosis of malignancy conﬁrmed in 10 of the 11 total pa-
tients. The total number of CPLNs resected from all patients was 21
with malignancy being conﬁrmed in 18 (86%).
Themedian number of post-operative days was 7 (range 4–37). The
overall post-operative morbidity associated with CPLN resection was
low with the most common ﬁnding being a small pleural effusion
Table 1
Pre-operative characteristics of patients undergoing CPLN resection.
Characteristics N (11 total patients) % Mean Range
Age 58 42–71
Pre-operative CA-125
b200 2 18
N200 9 82
Surgery
Primary 10 91
Recurrent 1 9
Neoadjuvant chemotherapy 2 20
CPLN on pre-op CT 7 64
Cancer site
Endometrial 1 9
Ovary 8 73
Peritoneal 1 9
Fallopian tube 1 9
Histology
Serous 8 73
Mucinous/serous 1 9
Endometrioid 1 9
Clear cell 1 9
Stage
IIIC 1 10
IVB 9 90
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noted on POD# 0–5 were small and moderate pleural effusion as well
as small apical pneumothorax. Major complications were rare (occur-
ring in 1 patient only) and consisted of respiratory failure with need
for re-intubation and eventual tracheostomy, which was not thought
to be related to the CPLN resection. No patients required post-operative
thoracentesis for effusion or pneumothorax. The average time to adju-
vant chemotherapy was similar in patients who received HIPEC versus
those who did not (39 and 38 days, respectively).
4. Discussion
Stage III or IV ovarian cancer by deﬁnition involves extrapelvic
spread of tumor, however it often presents with tumor involvement of
the diaphragm peritoneum and muscle, and has been reported to in-
volve cardiophrenic lymph nodes. In a survey of gynecologic oncologists
in 2001, 76.3% of respondents reported that bulky upper abdominal dis-
ease precluded complete cytoreductive surgery. In addition, only 24% of
respondents reported performing diaphragm resection, and 30% stated
they were not experienced with the procedure (Eisenkop and Spirtos,
2001).
Themorbidity andmortality associatedwith such complex and inva-
sive surgical procedures has been previously studied. Themost common
post-operative complications reported after undergoing diaphragmatic
surgery (either peritonectomy or muscle resection) were pleural effu-
sion (5–57%), pneumothorax (0–29%), and pneumonia (0–7%). Serious
complications occurred rarely and included pleural effusion requiring
thoracostomy or thoracentesis, need for re-operation, and death.
Many of these studies however further stratiﬁed each complication
based on grade/severity and post-operative day of occurrence, noting
that the majority of complications occurred on POD# 1–2, were of low
severity, and did not delay hospital discharge (Bashir et al., 2010; Chi
et al., 2010; Tsolakidis et al., 2010; Sandadi et al., 2014).
Despite such a proactive approach to the surgical cytroreduction of
advanced gynecologic cancer, the current small case series demon-
strates that transdiaphragmatic CPLN resection is feasible and is accom-
panied by acceptable postoperative morbidity. When compared to the
above reports of patients who underwent aggressive upper abdominal
surgery (UAS) for ovarian cancer, the post-operative morbidities we
identiﬁed did not differ signiﬁcantly nor did the procedure result in
any signiﬁcant prolongation of postoperative hospital stay. Panici et al.
reported that in a study of 120 patients who underwent UAS for ovariancancer, the median hospital stay for patients with and without compli-
cation was 7 vs. 13 days, respectively (Benedetti Panici et al., 2015). In
addition, Cliby et al. reported that diaphragm resection as part of
cytoreductive surgery for ovarian cancer carries comparable risks to
other radical debulking procedures (Cliby et al., 2004). The decision to
proceed with extensive cytoreductive procedures must be made care-
fully and with the intent to achieve cytroreduction to no gross residual
disease. Furthermore, multiple studies have demonstrated that patients
whohad optimal (b1 cm) ormicroscopic residual disease had increased
survival compared to those with suboptimal resection (Winter et al.,
2008; Aletti et al., 2006; Eisenhauer et al., 2006). Given that the size of
resected CPLNs in our study ranged from 0.2 to 2.5 cm, removal of me-
diastinal metastasis may make a signiﬁcant difference in the ability to
achieve optimal cytoreduction to b1.0 cm.
The short-term morbidity of the patients included in our study was
similar to previous reports of patients who underwent diaphragm re-
section or other aggressive upper abdominal surgery. As the majority
of the CPLN specimens were positive for malignancy, the addition of
this procedure contributed to achieving cytoreduction to NGR status.
This suggests that careful attention should be paid to the lowermedias-
tinum on pre-operative imaging of advanced gynecologic cancer pa-
tients — particularly when the diaphragm appears to be involved.
Currently, there is mixed data on the optimal time for initiation of
adjuvant chemotherapy after primary cytoreductive surgery. One of
the continually recognized prognostic factors for advanced ovarian can-
cer is residual disease at the conclusion of primary surgery. Aletti et al.
reported that time to chemotherapy (TTC)was not a predictor of overall
survival, and that concerns regarding the TTC interval should not be
used to justify a more conservative approach to primary debulking sur-
gery (Aletti et al., 2007). Although in our small case series TTC data was
only available for 7 patients, we found that the addition of CPLN resec-
tion did not largely delay initiation of adjuvant chemotherapy, and in
fact contributed to achieving R0 status as themajority of the CPLN spec-
imens were positive for malignancy. Furthermore, even in the subset of
our patients that had HIPEC performed during surgery, the initiation of
adjuvant chemotherapy was only increased by one day. Again however,
when considering the small number of patients included in our study, it
is difﬁcult to draw any statistical signiﬁcance from these speciﬁc
ﬁndings.
Some important limitations in our study must be noted before ap-
plying the described technique to routine clinical practice. First, we do
not yet have recurrence or survival data on the patients included.
Table 2
Intra- and post-operative ﬁndings in patients undergoing transdiaphragmatic CPLN resection.
Characteristics N (11 total patients) % Mean Range
Operative time 385 min 277–568
Estimated blood loss 564 cm3 200–900
Residual disease
No gross residual 7 64
b1 cm 3 27
N1 cm 1 9
Prophylactic chest tube placement 8 73
Ancillary procedures
Modiﬁed radical hysterectomy 8 73
BSO 9 82
Omentectomy 11 100
Pelvic LND 8 73
Para-aortic LND 8 73
Recto-sigmoid colectomy 8 73
Small bowel resection 1 9
Ileocecal resection 2 18
Hepatic resection 2 18
Splenectomy 4 36
Appendectomy 6 55
Colectomy 3 27
Partial gastrectomy 1 9
Distal pancreatectomy 2 18
Diaphragm peritonectomy 11 100
Diaphragm resection 10 91
Pan-pelvic peritonectomy 10 91
Argon beam ablation 5 45
HIPEC 6 55
Median Range
Post-op day of discharge 7 4–37
Days to adjuvant chemotherapy Mean
HIPEC performed 39 27–49
HIPEC not performed 38 28–53
Post-operative morbidities
Pleural effusions on POD 0–2
Small 4 36
Moderate 3 27
Pleural effusions on POD 3–5
Small 6 55
Moderate 2 18
Pneumothorax on POD 0–2 (small/apical) 3 27
Pneumothorax on POD 3–5 (small/apical) 3 27
Respiratory failure/reintubation 1 9
Tracheostomy 1 9
Post-operative pneumonia 1 9
Pulmonary embolism 1 9
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any greater risk than other similarly aggressive surgical procedures, it is
unclear as to whether it prolongs progression-free or overall survival.
Second, the procedure describedwas performed by a single gynecologic
oncologist at our institution. Although the majority of gynecologic on-
cologists receive adequate training during fellowship in the surgical
management of ovarian cancer, few may feel comfortable performing
such extensive and radical upper abdominal procedures. Third, despite
our attempt to achieve cytoreduction to NGR in all patients, 4/11 pa-
tients had residual disease (three with b1.0 cm, and one with
N1.0 cm). Although the resection of CPLNs certainly contributed to
achieving optimal cytoreduction to b1.0 cm in these three patients, an
alternative approach would be to perform this procedure last after en-
suring NGR in the remainder of the abdomen. Considering the impact
of tumor biology and initial disease burden on PFS/OS, itmay be prudent
to ensure ability to achieve NGR prior to performing this speciﬁc proce-
dure. Lastly, all patients had surgery performed at a major university-
based hospital with physicians and staff that were highly experienced
in managing potentially serious post-operative complications. Smaller
hospitals with less experienced consulting physicians and ancillary
staff may be reluctant to perform such aggressive surgical procedures
in fear of potentially catastrophic events.In conclusion, our small case series demonstrates the feasibility and
short-termmorbidities associatedwith transdiaphragmatic CPLN resec-
tion and describes an additional procedure used to achieve
cytoreduction to NGR in patients with advanced gynecologic
malignancies.
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